The clinical trial reached its milestone with participants receiving a 150 µg/kg dose of ZYNLONTA alongside glofitamab. Recruitment spanned 30 sites across the United States and Europe, drawing a patient population with a median age of 66. The cohort consists of 46% relapsed and 54% primary refractory patients, reflecting a challenging demographic for standard therapies.

Chief Medical Officer Mohamed Zaki noted that early efficacy data showed an 89.8% overall response rate and a 77.6% complete response rate among the first 49 evaluable patients. These results form the basis of the company's ambition to position the combination as a best-in-class treatment for second-line or later diffuse large B-cell lymphoma. While the primary focus remains on safety and tolerability, researchers are monitoring secondary outcomes including progression-free survival and duration of response. ADC Therapeutics intends to present the final findings at a medical conference later this year and will evaluate potential regulatory pathways for the combination therapy.